Pathophysiology
Excess cortisol suppresses ACTH (except in ACTH-dependent forms), drives gluconeogenesis, proteolysis, lipolysis with central redistribution, immunosuppression and mineralocorticoid receptor activation.
Sources: Endocrine Society CPG on Cushing Syndrome Treatment (J Clin Endocrinol Metab 2015;100:2807); Pituitary Society Consensus on Cushing Disease (Nat Rev Endocrinol 2021;17:337)
Clinical presentation
Central obesity, moon facies, buffalo hump, supraclavicular fat, purple abdominal striae (>1 cm), proximal myopathy, easy bruising, hypertension, glucose intolerance, hirsutism, osteoporosis, mood disturbance, poor wound healing.
Sources: Endocrine Society CPG on Cushing Syndrome Treatment (J Clin Endocrinol Metab 2015;100:2807); Pituitary Society Consensus on Cushing Disease (Nat Rev Endocrinol 2021;17:337)
Diagnosis
Screen: any two of - late-night salivary cortisol, 24-h urinary free cortisol, 1 mg overnight dexamethasone suppression test. Confirm hypercortisolism, then measure ACTH: suppressed -> adrenal imaging; normal/high -> high-dose dexamethasone and pituitary MRI +/- inferior petrosal sinus sampling.
Sources: Endocrine Society CPG on Cushing Syndrome Treatment (J Clin Endocrinol Metab 2015;100:2807); Pituitary Society Consensus on Cushing Disease (Nat Rev Endocrinol 2021;17:337)
Management
Iatrogenic: taper glucocorticoids. Pituitary adenoma: transsphenoidal resection (first-line, remission 70-90%). Adrenal tumour: adrenalectomy. Ectopic ACTH: resect source; medical therapy with ketoconazole, metyrapone, osilodrostat or mifepristone if surgery not feasible.
Sources: Endocrine Society CPG on Cushing Syndrome Treatment (J Clin Endocrinol Metab 2015;100:2807); Pituitary Society Consensus on Cushing Disease (Nat Rev Endocrinol 2021;17:337)
Complications
Cardiovascular disease (>4x mortality), diabetes, osteoporotic fractures, thromboembolism, opportunistic infections, and psychiatric morbidity even after biochemical cure.
Sources: Endocrine Society CPG on Cushing Syndrome Treatment (J Clin Endocrinol Metab 2015;100:2807); Pituitary Society Consensus on Cushing Disease (Nat Rev Endocrinol 2021;17:337)







